Table 1.

Current ongoing studies in pemphigus that target B cells or their pathogenic antibodies (excluding studies with rituximab).

A Long-Term Extension Study of Ofatumumab (type I anti-CD20) Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris ClinicalTrials.gov identifier: NCT02613910

Efficacy and Safety of Ofatumumab (type I anti-CD20) in Treatment of Pemphigus Vulgaris ClinicalTrials.gov identifier: NCT01920477

Study of Efficacy and Safety of VAY736 (anti-BAFF-R) in Patients With Pemphigus Vulgaris ClinicalTrials.gov identifier: NCT01930175

A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 (human IgG1-derived Fc fragment that binds to FcRn) in Patients With Pemphigus ClinicalTrials.gov identifier: NCT03334058

A Safety Study of SYNT001 (A Humanized IgG4 Monoclonal Antibody That Disrupts the Interaction of FcRn and IgG) in Subjects With Pemphigus (Vulgaris or Foliaceus) ClinicalTrials.gov identifier: NCT03075904

A Study of PRN1008 (Bruton’s tyrosine kinase inhibitor) in Adult Patients With Pemphigus Vulgaris ClinicalTrials.gov identifier: NCT02704429

Bold represents mechanisms of action of the drug.

FcRn, neonatal Fc Receptors.

New therapies seek to disrupt the IgG–FcRn interaction to increase the clearance of pathogenic IgG antibodies from the body.